The COVID-19 vaccine market shifted from a federally-purchased, no-cost product to a standard commercial pharmaceutical starting in 2024, when the U.S. government's bulk-purchase contracts with Pfizer-BioNTech and Moderna expired. Comirnaty (Pfizer-BioNTech), Spikevax and mNexspike (Moderna), and Nuvaxovid (Novavax, approved in the U.S. in May 2025) now move through the same billing channels as any other vaccine: Medicare Part B, Medicaid, commercial insurance claims, or a cash-pay pharmacy visit. The FDA narrowed its 2025-2026 and 2026-2027 approvals to adults 65 and older and people 5 to 64 with at least one underlying condition that raises COVID-19 risk, such as diabetes, asthma, obesity, pregnancy, or a weakened immune system. Healthy people under 65 without a qualifying condition fall outside the FDA-labeled indication, which changes both pharmacy access and, in some states, insurance coverage.
Cash-pay pricing for the 2026-2027 formula runs from about $134 at the CDC's published federal reference price up to $299 at some retail pharmacy chains, before any separate administration fee. Medicare beneficiaries pay $0 because Congress placed COVID-19 vaccination under the Medicare Part B preventive-vaccine benefit in the CARES Act, the same statutory category as the flu and pneumococcal vaccines, so the $283 Part B deductible for 2026 never applies to this shot. Medicaid programs have covered ACIP-recommended adult vaccines, including COVID-19, with no cost-sharing since October 1, 2023, under a mandate in the Inflation Reduction Act. Commercially insured patients generally pay $0 too, as long as the shot is given in-network and the vaccine still carries an ACIP recommendation, even the narrower 2025 individual-decision-making recommendation that now applies to people under 65.
Pfizer, Moderna, and Novavax do not sell manufacturer copay cards for their COVID-19 vaccines the way they do for chronic-disease drugs, because insured patients already pay $0 by law and no prior authorization or formulary tier applies to an in-network Part B or ACA preventive vaccine. Instead, each company runs a separate access channel for the uninsured. Pfizer RxPathways supplies free Comirnaty through a patient's own doctor's office for households at or below 300% of the federal poverty level. Moderna routes free Spikevax and mNexspike doses through Direct Relief and Project HOPE, which supply Federally Qualified Health Centers and free clinics rather than accepting individual applications. This guide breaks down the 2026 cost by payer, the pharmacy price comparison, and what to do if you get an unexpected bill for a shot that should have cost $0.
What COVID-19 Vaccine Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same covid-19 vaccine can cost many times more at a hospital than at your local pharmacy:
2026 COVID-19 Vaccine Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Medicare Part B (2026-2027 season) | $0/dose (no deductible, no coinsurance) | Preventive vaccine benefit. CMS pays providers $230.41 for Comirnaty (CPT 91320), $172.97-$252.23 for other brands, plus a $44.95 administration fee. |
| Pharmacy counter (retail, cash, uninsured) | $134 - $299/dose | Price varies by brand and pharmacy; some locations add a separate office-visit or administration charge. |
| Commercial insurance (in-network) | $0/dose | Required by the ACA preventive-services mandate for an ACIP-recommended vaccine given in-network. No prior authorization needed for on-label use; out-of-network visits can trigger balance billing. |
| Medicaid | $0/dose | No-cost-sharing mandate for ACIP-recommended adult vaccines, effective October 1, 2023, under the Inflation Reduction Act. |
| Patient assistance program (uninsured) | $0/dose | Pfizer RxPathways (Comirnaty) or Moderna's Direct Relief and Project HOPE clinic network (Spikevax, mNexspike); income and documentation rules apply. |
Retail cash prices reflect 2026 GoodRx and pharmacy chain data. Medicare and Medicaid figures reflect the 2026-2027 CMS vaccine pricing file and federal cost-sharing mandates.
Source: CMS 2026-2027 Seasonal Influenza and COVID-19 Vaccine Pricing File, CDC Adult COVID-19 Vaccine Price List, Pfizer RxPathways, Moderna COVID-19 Vaccine Access
Why Hospitals Charge So Much
Hospitals rarely bill a standalone COVID-19 vaccine dose because most people get their shot at a retail pharmacy or physician's office, not during an inpatient stay. When a hospital does administer and bill a dose, usually for a patient already admitted for another reason, the charge can run several times the $230.41 Medicare product rate for Comirnaty. Facility fees, pharmacy handling charges, and nursing administration time get layered on top of the vaccine's acquisition cost, the same markup pattern seen with other injectable drugs given in a hospital setting.
Original Medicare pays the hospital the same $0 patient cost-share and a fixed product-plus-administration rate regardless of the facility's list price, so an inpatient charge of $500 or more for a single dose is a billing pattern worth disputing, not a true out-of-pocket cost. Ask for an itemized bill and the CPT code (91320 for Comirnaty, 91322 for Spikevax, 91323 for mNexspike, or 91304 for Nuvaxovid), and confirm the claim was submitted to Part B rather than billed as a self-pay cash charge.
HCPCS J-Codes: What Appears on Your Bill
COVID-19 vaccines do not use HCPCS Level II J-codes like infused biologics. Instead, Medicare and most payers bill the vaccine product and its administration under separate CPT codes for the 2026-2027 season.
HCPCS J-codes for COVID-19 Vaccine| Code | Description | What to look for |
|---|
| 91320 | Comirnaty (Pfizer-BioNTech), 30 mcg, ages 12 and up, 2026-2027 formula | Medicare pays $230.41/dose in the 2026-2027 season. Confirm this exact code appears rather than a generic unspecified-vaccine line. |
| 91322 | Spikevax (Moderna), 50 mcg, ages 12 and up | Medicare pays $172.97/dose in the 2026-2027 season. |
| 91323 | mNexspike (Moderna), 10 mcg lower-dose formulation, ages 65+ or 12-64 with a risk condition | Medicare pays $252.23/dose in the 2026-2027 season, the highest of the four products. |
| 91304 | Nuvaxovid (Novavax), 5 mcg, protein subunit vaccine | Medicare pays $232.22/dose in the 2026-2027 season. Approved only for ages 65+ or 12-64 with a qualifying underlying condition. |
| 90480 | Vaccine administration, single dose, any COVID-19 vaccine | Medicare pays a $44.95 administration fee ($39.90 for in-home administration under code M0201). This fee should appear once per dose, not multiple times. |
Rates are the national Medicare Part B payment allowances effective for dates of service on or after August 27, 2026. Commercial insurers and Medicaid programs set their own negotiated rates, but patient cost-sharing is $0 in nearly all cases.
Source: CMS 2026-2027 Seasonal Influenza and COVID-19 Vaccine Pricing File
Patient Assistance Programs
Pfizer and Moderna do not run manufacturer copay cards for their COVID-19 vaccines because insured patients already pay $0 by law. For uninsured patients, each manufacturer instead runs a separate no-cost access channel outside the standard insurance system.
Patient assistance programs for COVID-19 Vaccine| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Pfizer RxPathways | Free Comirnaty for uninsured patients at or below 300% of the federal poverty level, dispensed through the patient's doctor's office | pfizerrxpathways.com |
| Moderna COVID-19 Vaccine Access (Direct Relief and Project HOPE) | Free Spikevax or mNexspike distributed through enrolled Federally Qualified Health Centers and Free and Charitable Clinics; no direct individual application | modernatx.com/products/covid-19-vaccine-access |
| HRSA Health Center Locator | Finds a Federally Qualified Health Center near you that offers sliding-scale or free vaccines regardless of insurance status | findahealthcenter.hrsa.gov |
| NeedyMeds Vaccine and Drug Discount Directory | Directory of free and reduced-cost vaccine clinics and manufacturer programs | needymeds.org |
Federal anti-kickback statute (42 U.S.C. Section 1320a-7b) generally bars manufacturers from offering copay coupons to Medicare, Medicaid, TRICARE, or VA beneficiaries, which is one reason neither Pfizer nor Moderna offers a discount card for this vaccine. It rarely matters in practice because Medicare and Medicaid already cover the vaccine at $0; the income-based Pfizer RxPathways program and Moderna's clinic network exist specifically for people with no insurance at all.
Source: Pfizer RxPathways, Moderna COVID-19 Vaccine Access, HRSA, NeedyMeds.org
Common COVID-19 Vaccine Billing Errors
If you were charged anything for a COVID-19 vaccine while covered by Medicare, Medicaid, or an in-network commercial plan, check for these common billing mistakes before paying.
- Cost-sharing applied to a Medicare Part B claim: your dose should show $0 patient responsibility, with no deductible or coinsurance, because COVID-19 vaccination is a Part B preventive benefit, not a Part D drug sitting on a formulary tier.
- Vaccine billed as an out-of-network self-pay charge when your in-network pharmacy or clinic administered it: ask the biller to resubmit through your insurance rather than accepting a cash-pay receipt.
- Wrong CPT product code used, for example Comirnaty's 91320 billed when you actually received Spikevax's 91322: this can trigger a coverage denial even though the vaccine itself was free.
- Administration fee (CPT 90480) charged twice for a single dose, once by the pharmacy and once by a separate clinical staffing company.
- Prescription requirement confusion: some pharmacies in certain states now require a prescription for patients outside the FDA-approved age or risk-condition group, and bill a separate office-visit fee if a prescription had to be written on-site.
- Uninsured patient charged full cash price without being told about Pfizer RxPathways or Moderna's Direct Relief and Project HOPE clinic network.
Frequently Asked Questions
Is there a generic version of the COVID-19 vaccine?
No generic or biosimilar COVID-19 vaccine exists in 2026. Comirnaty (Pfizer-BioNTech), Spikevax and mNexspike (Moderna), and Nuvaxovid (Novavax) are three separate brand-name products, each with its own patents and manufacturing process, and none has a generic equivalent the way a small-molecule drug like atorvastatin does. Switching between brands is the closest thing to a generic option, and all three manufacturers are priced and covered similarly under Medicare Part B, Medicaid, and commercial insurance.
How do I apply for Pfizer's patient assistance program for the COVID-19 vaccine?
Ask your doctor's office to enroll you in Pfizer RxPathways, the manufacturer's patient assistance program for Comirnaty. First, confirm you have no health insurance and a household income at or below 300% of the federal poverty level. Next, have your provider submit the RxPathways enrollment form with proof of income and residency. Once approved, Pfizer ships free vaccine doses directly to the provider's office for administration. If you don't have a regular doctor, a Federally Qualified Health Center found through findahealthcenter.hrsa.gov can both enroll you and administer the dose.
Can I use a manufacturer coupon for the COVID-19 vaccine with Medicare?
No, and you generally would not need one. Pfizer and Moderna do not offer manufacturer coupons or copay cards for their COVID-19 vaccines because federal law already requires Medicare Part B, Medicaid, and in-network commercial plans to cover the shot at $0 out-of-pocket. Manufacturer coupons for Medicare beneficiaries are also restricted by the federal anti-kickback statute, the same rule that blocks copay cards for chronic-disease drugs like Eliquis or Ozempic. If you are uninsured, use Pfizer RxPathways or Moderna's Direct Relief and Project HOPE network instead of looking for a coupon.
What if my insurance denies coverage or bills me for the COVID-19 vaccine?
Start by confirming the claim was billed correctly: in-network administration of an ACIP-recommended vaccine should show $0 patient responsibility under Medicare Part B, Medicaid, or an ACA-compliant commercial plan, and typically does not require prior authorization. If you were billed, file a written appeal citing the preventive-services mandate and ask your pharmacy or clinic to resubmit the claim with the correct CPT code. If you are under 65 without a qualifying risk condition, your plan may deny coverage because the 2025-2026 FDA label narrowed routine use, so ask your doctor to document a risk factor like obesity, pregnancy, or a chronic lung condition to support medical necessity.
Does the Inflation Reduction Act's Maximum Fair Price apply to the COVID-19 vaccine?
No. The Inflation Reduction Act's drug price negotiation program, which produced 2026 Maximum Fair Prices for 10 Medicare Part D drugs like Eliquis and Jardiance, applies only to high-spend Part D and Part B drugs selected by CMS. COVID-19 vaccines are Part B preventive-vaccine benefits, not negotiated drugs, and there is no Maximum Fair Price for them in 2026. Instead, Medicare pays CMS-set per-dose vaccine rates, $230.41 for Comirnaty for example, directly to providers, and the beneficiary's cost is always $0.
What does the COVID-19 vaccine cost without insurance at the pharmacy in 2026?
Cash-pay prices for the 2026-2027 formula run from about $134 per dose at Costco up to $299 at some CVS locations, depending on the brand and site. GoodRx-tracked prices in September 2026 showed roughly $134 at Costco, $143 at Walgreens, and $160 with a coupon at CVS, though CVS's posted uninsured cash rate without a discount can run as high as $250 to $299. If those prices feel out of reach, Pfizer RxPathways and Moderna's Direct Relief and Project HOPE network both provide free doses to eligible uninsured patients.
Do I qualify for Pfizer's patient assistance program for the COVID-19 vaccine?
You generally qualify for Pfizer RxPathways if you have no health insurance of any kind and your household income is at or below 300% of the federal poverty level, for example $47,880 for a single person or $99,000 for a family of four in 2026. You'll also need a valid prescription or referral from a participating doctor's office or Federally Qualified Health Center, since Pfizer ships free doses to providers rather than directly to patients. Common denial reasons include having any active insurance coverage, incomplete income documentation, or applying through a provider not enrolled in RxPathways.
Why can't a healthy 40-year-old get a COVID-19 vaccine covered the way a 70-year-old can?
The FDA narrowed its 2025-2026 and 2026-2027 approvals for Comirnaty, Spikevax, mNexspike, and Nuvaxovid to adults 65 and older and people 5 to 64 with at least one underlying condition, such as diabetes, obesity, asthma, pregnancy, or a weakened immune system. A healthy 40-year-old without a listed condition falls outside the FDA-labeled indication, so some pharmacies require a prescription and some insurers may question the claim, even though ACIP still allows the shot under a 2025 individual-decision-making recommendation. If you have a condition that qualifies but isn't obvious, like a BMI over 30 or a smoking history, ask your doctor to document it on the order.
